



Press release
2008-04-10

The Annual General Meeting of Tripep AB

The Annual General Meeting of Tripep AB was held in Stockholm on 9 April, 2008.

Annual Report and discharge from liability

The company's Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer were discharged from liability for the financial year 2007.

Election of Board of Directors and Chairman of the Board and compensation to the Board

Thomas Lynch, Anders Vahlne and Matti Sällberg were appointed to the Board of Directors, (all re-elected).

Thomas Lynch was re-elected as Chairman of the Board.

The Meeting resolved that no directors' fees shall be payable.

Reversed stock split

The Meeting approved the Board's proposal to carry out a reversed stock split 1:10 and to amend the articles of association accordingly. The Board of Directors was authorized to resolve the record date.

Authorisation to issue shares, convertibles debentures and warrants

The Meeting authorized the Board of Directors to resolve, at one or more occasions until the next Annual General Meeting, to issue new shares, convertible debentures and/or warrants with consideration in cash or in kind or by set-off or otherwise with conditions and thereby be able to resolve to disapply the shareholders pre-emption rights.

Nomination Committee

The Annual General Meeting resolved to appoint a Nomination Committee comprising the Chairman of the Board Thomas Lynch, Erik Selin and Peter Horal. The task of the Nomination Committee is to submit proposals for Board members and Board fees ahead of the Annual General Meeting 2009.

For more information, please contact:

Jan Nilsson, CEO, Tripep AB

Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se

Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal and a therapeutic vaccine against Hepatitis C, named ChronVac-C[®], plus the RAS[®] technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's website: www.tripep.se.